AHSCT (n=69) | ALZ (n=75) | P value | |
Centre (n) | |||
Uppsala/Sahlgrenska | 60/9 | 4/71 | <0.0001*** |
Sex (n) | |||
Men/women | 20/49 | 33/42 | 0.09*** |
Age (years) | 30 (IQR 26–37) | 35 (IQR 30–41) | 0.005* |
Disease duration (years) | 6.4 (±5.7) | 7.0 (±5.4) | 0.5* |
Number of previous treatments (n) | 2 (IQR 1–3) | 2 (IQR 1–3) | 0.8** |
Treatment naive | 8 | 11 | |
Dimethylfumarate | 8 | 9 | |
Glatiramer acetate | 13 | 5 | |
Interferon beta | 37 | 36 | |
IVIG | 4 | 1 | |
Teriflunomide | 2 | 4 | |
Cladribine | 0 | 1 | |
Fingolimod | 15 | 32 | |
Mitoxantrone | 2 | 1 | |
Natalizumab | 33 | 57 | |
Rituximab | 17 | 3 | |
ARR 1 year prior to treatment | 1.4 (±1.2) | 0.54 (±0.81) | <0.0001* |
Baseline EDSS | 3 (IQR 2–4) | 2 (IQR 1–2.5) | <0.0001** |
Baseline ARMSSS | 6.1 (IQR 4.2–7.3) | 4.1 (2.0–5.5) | <0.0001** |
*Student’s t-test, **Mann-Whitney’s test, ***χ² test.
AHSCT, autologous haematopoietic stem cell transplantation; ALZ, alemtuzumab; ARMSSS, age-related multiple sclerosis severity score; ARR, annualised relapse rate.